Purkayastha Joydeep, Yadav Jitin, Talukdar Abhijit, Das Gaurav, Pegu Niju, Madhav Srishti, Singh Pritesh R, Mamidala Vinay
1Department of Surgical Oncology, Dr. B. Borooah Cancer Institute, Gopinath Nagar, Guwahati, 781016 India.
Department of Prosthodontics, Dental College, Azamgarh, India.
Indian J Surg Oncol. 2020 Mar;11(1):66-70. doi: 10.1007/s13193-019-00990-x. Epub 2019 Nov 5.
Gastric cancer (GC) is common in the northeast and southern parts of India. Radical surgery is the cornerstone of treatment and offers the only chance for cure. This study was conducted to assess the outcomes of all resectable gastric cancers that presented to our tertiary cancer center in Northeast India. All patients undergoing upfront surgery for gastric cancer with curative intention between 2012 and 2017 were included in the study. A total of 116 patients who underwent upfront radical gastrectomy were included in the study. Males (58.6%) were more common than females (41.4%). Mean age at presentation was 56.12 years (range 26-89). The most common mode of presentation was pain abdomen (53.8%). The most common location of tumor was the distal part (81%) followed by the proximal part (10.3%). The most commonly done procedure was distal radical gastrectomy (56.9%) followed by subtotal gastrectomy (32.8%). Median number of lymph nodes isolated was 14. Fifty-four patients received adjuvant chemotherapy while 32 patients received adjuvant chemoradiation (CTRT). At a median follow-up of 14 months (range, 2-78 months), overall 5-year survival was 23.75% (mean survival 33.77 months, median survival 24 months). The 5-year survival for stages I-III was 100%, 26.25%, and 11.25%, respectively ( < 0.001). Though perioperative chemotherapy has a role in gastric cancer, it is not the substitute for radical D2 gastrectomy which is still the gold standard treatment especially in high-volume centers.
胃癌（GC）在印度东北部和南部地区较为常见。根治性手术是治疗的基石，也是治愈的唯一机会。本研究旨在评估所有就诊于印度东北部我们的三级癌症中心的可切除胃癌的治疗结果。2012年至2017年间所有接受以治愈为目的的胃癌初次手术的患者均纳入本研究。共有116例接受初次根治性胃切除术的患者纳入研究。男性（58.6%）比女性（41.4%）更常见。就诊时的平均年龄为56.12岁（范围26 - 89岁）。最常见的表现方式是腹痛（53.8%）。肿瘤最常见的部位是远端（81%），其次是近端（10.3%）。最常进行的手术是远端根治性胃切除术（56.9%），其次是胃次全切除术（32.8%）。分离出的淋巴结中位数为14个。54例患者接受了辅助化疗，32例患者接受了辅助放化疗（CTRT）。中位随访14个月（范围2 - 78个月），总体5年生存率为23.75%（平均生存33.77个月，中位生存24个月）。I - III期的5年生存率分别为100%、26.25%和11.25%（<0.001）。尽管围手术期化疗在胃癌治疗中发挥作用，但它不能替代根治性D2胃切除术，根治性D2胃切除术仍然是金标准治疗，尤其是在大容量中心。
